Research ArticleSpondyloarthritis
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng and Annelies Boonen
The Journal of Rheumatology August 2021, 48 (8) 1259-1267; DOI: https://doi.org/10.3899/jrheum.201088
Peter C. Taylor
1P.C. Taylor, PhD, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;
Désirée van der Heijde
2D. van der Heijde, MD, Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands;
Robert Landewé
3R. Landewé, MD, Amsterdam University Medical Center, Amsterdam, and Zuyderland Medical Center, Heerlen, the Netherlands;
Shannon McCue
4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;
Sue Cheng
4S. McCue, PhD, S. Cheng, MD, Amgen Inc., Thousand Oaks, California, USA;
Annelies Boonen
5A. Boonen, PhD, Division of Rheumatology, Department of Internal Medicine, Maastricht University Medical Center, and Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands.
REFERENCES
- 1.↵
- 2.↵
- 3.↵
- Braun J,
- van den Berg R,
- Baraliakos X,
- Boehm H,
- Burgos-Vargas R,
- Collantes-Estevez E, et al.
- 4.↵
- Ward MM,
- Deodhar A,
- Akl EA,
- Lui A,
- Ermann J,
- Gensler LS, et al.
- 5.↵
- van der Heijde D,
- Ramiro S,
- Landewé R,
- Baraliakos X,
- Van den Bosch F,
- Sepriano A, et al.
- 6.↵Otezla [package insert]. [Internet. Accessed April 29, 2021.] Available from: www.pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/otezla/otezla_pi_english.ashx
- 7.↵
- 8.↵
- Schafer PH,
- Chen P,
- Fang L,
- Wang A,
- Chopra R.
- 9.↵
- 10.↵
- Pathan E,
- Abraham S,
- Van Rossen E,
- Withrington R,
- Keat A,
- Charles PJ, et al.
- 11.↵
- 12.↵
- Sieper J,
- Rudwaleit M,
- Baraliakos X,
- Brandt J,
- Braun J,
- Burgos-Vargas R, et al.
- 13.↵
- 14.↵
- 15.↵
- Lukas C,
- Landewé R,
- Sieper J,
- Dougados M,
- Davis J,
- Braun J, et al.
- 16.↵
- Heuft-Dorenbosch L,
- Spoorenberg A,
- van Tubergen A,
- Landewé R,
- van ver Tempel H,
- Mielants H, et al.
- 17.↵
- Creemers MC,
- Franssen MJ,
- van’t Hof MA,
- Gribnau FW,
- van de Putte LB,
- van Riel PL.
- 18.↵
- Lukas C,
- Braun J,
- van der Heijde D,
- Hermann KG,
- Rudwaleit M,
- Østergaard M, et al.
- 19.↵
- Maksymowych WP,
- Mallon C,
- Morrow S,
- Shojania K,
- Olszynski WP,
- Wong RL, et al.
- 20.↵
- 21.↵
- 22.↵
- 23.↵
- Kavanaugh A,
- Mease PJ,
- Gomez-Reino JJ,
- Adebajo AO,
- Wollenhaupt J,
- Gladman DD, et al.
- 24.↵
- Cutolo M,
- Myerson GE,
- Fleischmann R,
- Lioté F,
- Díaz-González F,
- Van den Bosch F, et al.
- 25.↵
- 26.↵
- Edwards CJ,
- Blanco FJ,
- Crowley J,
- Birbara CA,
- Jaworski J,
- Aelion J, et al.
- 27.↵
- Papp K,
- Reich K,
- Leonardi CL,
- Kircik L,
- Chimenti S,
- Langley RG, et al.
- 28.↵
- Paul C,
- Cather J,
- Gooderham M,
- Poulin Y,
- Mrowietz U,
- Ferrandiz C, et al.
In this issue
The Journal of Rheumatology
Vol. 48, Issue 8
1 Aug 2021
A Phase III Randomized Study of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Active Ankylosing Spondylitis
Peter C. Taylor, Désirée van der Heijde, Robert Landewé, Shannon McCue, Sue Cheng, Annelies Boonen
The Journal of Rheumatology Aug 2021, 48 (8) 1259-1267; DOI: 10.3899/jrheum.201088